Ginkgo Bioworks Holdings Inc (DNA) Q2 2024 Earnings Call Highlights: Strategic Restructuring ...
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 48%
Lesaffre Strengthens Its Research, Development & Innovation (RD&I) With the Acquisition of Altar, a Company Owned by Ginkgo Bioworks
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing
NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
TD Cowen analyst Brendan Smith maintains $Ginkgo Bioworks(DNA.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 42.1% and a